US regulators sue ‘pharma bro’ Shkreli over drug monopoly
The US Federal Trade Commission (FTC) and New York’s attorney general have sued incarcerated ‘pharma bro’ Martin Shkreli for allegedly monopolising the market for life-saving drug Daraprim (pyrimethamine).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 May 2022 The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
30 July 2020 Jailed ‘pharma bro’ Martin Shkreli has told a US federal court he is not responsible for antitrust violations alleged by the US Federal Trade Commission.
16 April 2020 Six state attorneys have joined a suit filed against incarcerated ‘pharma bro’ Martin Shkreli and his company Vyera Pharmaceuticals for allegedly monopolising the market for a life-saving drug.